Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-02-10

Clinical Trial Update: Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 safety study evaluating weekly semaglutide in Chilean adults with Type 2 diabetes has completed, with results posted on 2025-02-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OZEMPIC (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2025-02-10